EWA
RCKT icon

EverSource Wealth Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

EverSource Wealth Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Buy
5,539
+147
+3% +$489 ﹤0.01% 2470
2026
Q1 		$19.3K Buy
5,392
+2,581
+92% +$10.3K ﹤0.01% 2525
2025
Q4 		$9.87K Buy
2,811
+297
+12% +$1.02K ﹤0.01% 2798
2025
Q3 		$8.2K Buy
2,514
+915
+57% +$2.88K ﹤0.01% 2924
2025
Q2 		$3.92K Buy
1,599
+1,376
+617% +$6.97K ﹤0.01% 3258
2025
Q1 		$1.49K Buy
223
+136
+156% +$1.34K ﹤0.01% 3072
2024
Q4 		$1.09K Buy
+87
New +$1.31K ﹤0.01% 2933
2024
Q1 		– Sell
-80
Closed -$2.4K – 2974
2023
Q4 		$2.4K Buy
+80
New +$1.77K ﹤0.01% 2118

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EverSource Wealth Advisors's RCKT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Rocket Pharmaceuticals (RCKT) stake by 2.7% in Q2 2026, buying an estimated $489 and bringing the position to 5,539 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

EverSource Wealth Advisors first reported a position in RCKT in Q4 2023 and has held it in 8 quarters since. The position peaked at $19.3K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • EverSource Wealth Advisors held 5,539 shares of Rocket Pharmaceuticals worth $18.9K as of Q2 2026.
  • EverSource Wealth Advisors bought 147 Rocket Pharmaceuticals shares in Q2 2026, an estimated $489.
  • Rocket Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2470 holding.
  • EverSource Wealth Advisors first reported a position in Rocket Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • EverSource Wealth Advisors's Rocket Pharmaceuticals position peaked at $19.3K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.